Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 5/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778294 | 0.83 | EPAS1 (0.44) | EPAS1HSPB1ALDH1A1 | |
| SCHEMBL18631963 | 0.80 | EPAS1 (0.42) | CA2CA9CA1CA12EPAS1 | |
| SCHEMBL3746820 | 0.80 | PTGS2 (0.43) | EPAS1HSPB1ALDH1A1 | |
| SCHEMBL15763982 | 0.79 | HSPB1 (0.44) | EPAS1HSPB1ALDH1A1 | |
| SCHEMBL3372590 | 0.79 | CA2 (0.50) | CA2CA9CA1CA12STS | |
| Lithium Ion SCHEMBL17456603 | 0.78 | EPAS1 (0.44) | EPAS1HSPB1SOS1 | |
| SCHEMBL15763949 | 0.78 | HSPB1 (0.42) | EPAS1HSPB1ALDH1A1 | |
| SCHEMBL15763983 | 0.78 | HSPB1 (0.46) | EPAS1HSPB1ALDH1A1 | |
| SCHEMBL17456607 | 0.78 | EPAS1 (0.41) | CA2CA9CA1CA12EPAS1 | |
| SCHEMBL4137310 | 0.77 | KDM4E (0.44) | EPAS1HSPB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | CA2 1381/4885CA9 1834/4885CA1 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.